Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract
- PMID: 15592025
- DOI: 10.1097/01.ju.0000148272.77539.2d
Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract
Abstract
Purpose: Prostaglandin E2, produced by cyclooxygenase (COX)-2, affects the behavior of tumor cells possibly through 1 of the prostaglandin E2 receptors, the EP4 receptor (EP4R). The relationship between tumor development and EP4R in transitional cell carcinoma of the upper urinary tract (TCC-UUT) has not been fully understood. We determined the relationships between clinicopathological features and prognosis with expressions of COX-2 and EP4R in nonmetastatic TCC-UUT.
Materials and methods: We examined expressions of COX-2 and EP4R by immunohistochemical technique in 101 patients. Histological features including tumor grade, pT stage and lymph node metastasis were examined using formalin fixed and paraffin embedded specimens from the radical operation. The predictive values of these expressions of prognosis were investigated by Kaplan-Meier curve and Cox proportional hazards analysis in multivariate model.
Results: Expression of COX-2 and EP4R was observed in 46 (45.5%) and 51 (50.5%) cases, respectively. Each expression was significantly associated with pT stage and grade. Patients with co-expression of these proteins had a higher frequency of extra-urinary tract recurrence (33.3%). Postoperative survival time of patients with co-expression of COX-2 and EP4R was significantly shorter than that of patients with other expression patterns (p <0.001). Although COX-2 or EP4R expression was not an independent factor for cause specific survival in a multivariate model, co-expression of these proteins was an independent one (odds ratio 12.26 and p = 0.0038).
Conclusions: Co-expression of COX-2 and EP4R is a potentially useful marker for tumor progression and survival in patients with nonmetastatic TCC-UUT.
Similar articles
-
Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.J Urol. 2003 Sep;170(3):985-9. doi: 10.1097/01.ju.0000080401.85145.ee. J Urol. 2003. PMID: 12913755
-
Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.Urology. 2004 Mar;63(3):602-8. doi: 10.1016/j.urology.2003.09.035. Urology. 2004. PMID: 15028476
-
The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter.Int J Urol. 2005 Nov;12(11):941-7. doi: 10.1111/j.1442-2042.2005.01159.x. Int J Urol. 2005. PMID: 16351648
-
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.J Urol. 2003 Mar;169(3):938-42. doi: 10.1097/01.ju.0000043638.89552.ed. J Urol. 2003. PMID: 12576817
-
Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival.Clin Cancer Res. 2003 May;9(5):1741-9. Clin Cancer Res. 2003. PMID: 12738729
Cited by
-
Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer.Molecules. 2020 Jan 29;25(3):575. doi: 10.3390/molecules25030575. Molecules. 2020. PMID: 32013065 Free PMC article. Review.
-
Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma.Br J Cancer. 2013 Jun 11;108(11):2312-20. doi: 10.1038/bjc.2013.216. Epub 2013 May 14. Br J Cancer. 2013. PMID: 23674090 Free PMC article.
-
E-type prostanoid receptor 4 (EP4) in disease and therapy.Pharmacol Ther. 2013 Jun;138(3):485-502. doi: 10.1016/j.pharmthera.2013.03.006. Epub 2013 Mar 21. Pharmacol Ther. 2013. PMID: 23523686 Free PMC article. Review.
-
Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions.Med Oncol. 2023 Jan 17;40(2):80. doi: 10.1007/s12032-022-01928-0. Med Oncol. 2023. PMID: 36650399 Free PMC article. Review.
-
Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature.Transl Androl Urol. 2016 Oct;5(5):720-734. doi: 10.21037/tau.2016.09.07. Transl Androl Urol. 2016. PMID: 27785429 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials